View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
May 29, 2020

CVMD clinical trial disruptions due to Covid-19; studies slow to resume investigation of diabetes drugs intensifies

By Victoria Smith

Covid-19 has caused multiple disruptions to the clinical trial landscape, extending to studies in all therapy areas, including those in the cardiovascular and metabolic disorder (CVMD) field. Since the beginning of the year, numerous trials postponed their estimated start dates, with some suspended and others postponed indefinitely.

While the futures of a large number of trials affected by the pandemic remain uncertain, some have resumed activity. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena